Sign Up to like & get
recommendations!
0
Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.773
Abstract: Vemurafenib is a BRAF kinase inhibitor indicated for the treatment of patients with BRAFV600 mutation–positive unresectable or metastatic melanoma and Erdheim‐Chester disease. This phase 1, open‐label, single‐arm study was designed to estimate absolute bioavailability of…
read more here.
Keywords:
mutation positive;
bioavailability;
absolute bioavailability;
patients brafv600 ... See more keywords